Swirsky Douglas J 4

What Happened
Douglas J. Swirsky, a director of Cellectar Biosciences, was granted a derivative award for 37,500 shares on July 7, 2026. The grant is reported at $0.00 per share (no cash paid at grant). The award is a compensated equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-07; Form 4 filed: 2026-07-08 (timely filing).
• Instrument: Derivative award/option-type grant for 37,500 shares reported at $0.00.
• Vesting: The award "shall vest in full on July 7, 2027," subject to continued service (footnote).
• Shares owned after transaction: Not specified in this Form 4.
• Filing timeliness: Filed the next calendar day (no late-file indication).

Context
This is a compensation-related equity grant typical for directors; it is not an open-market purchase or sale and does not by itself signal buying or selling intent. As a derivative award, its eventual value to the insider depends on future vesting and Cellectar’s stock price at the time of vesting or conversion.